Furthermore, considering the regulatory role of FcγRIIB at the level of the DC, it can be hypothesized that anti-FcγRIIB mAbs in combination with anti-CD20 mAbs (131) (clinical trial NCT02933320, see below) may favor enhanced activation of DCs by ICs following ADCC, migration to lymph nodes and stimulation of anti-tumor T cells. This evidence concerns the gene FCGR2B and neoplasm.